# BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma

> **NCT06608940** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Case Comprehensive Cancer Center**

## Conditions studied

- Hepato Cellular Carcinoma (HCC)

## Interventions

- **DRUG:** BC3402
- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT06608940
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-11
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-01-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Funding unavailable
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06608940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06608940, "BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06608940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*